Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

Semaglutide was found to reduce the occurrence of major adverse cardiovascular events (MACE) by 20% in patients with a ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...